- Markets
- Healthcare
- ASPIRA
ASPIRA
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Aspira Pathlab & Diagnostics Along With Two Other Designated Partners Incorporated Llp
April 4 (Reuters) - Aspira Pathlab & Diagnostics Ltd ASPR.BO:
ASPIRA PATHLAB & DIAGNOSTICS LTD - CO ALONG WITH TWO OTHER DESIGNATED PARTNERS INCORPORATED LLP
Source text for Eikon: ID:nBSE8FwGRB
Further company coverage: ASPR.BO
(([email protected];))
April 4 (Reuters) - Aspira Pathlab & Diagnostics Ltd ASPR.BO:
ASPIRA PATHLAB & DIAGNOSTICS LTD - CO ALONG WITH TWO OTHER DESIGNATED PARTNERS INCORPORATED LLP
Source text for Eikon: ID:nBSE8FwGRB
Further company coverage: ASPR.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Aspira Pathlab&Diagn do?
Aspira Pathlab & Diagnostics Limited specializes in operating laboratories for a wide range of pathological investigations across multiple branches of healthcare.
Who are the competitors of Aspira Pathlab&Diagn?
Aspira Pathlab&Diagn major competitors are Constronics Infra, Choksi Lab, NG Industries, Tejnaksh Healthcare, Aatmaj Healthcare, Sangani Hospitals, Medinova Diagnostic. Market Cap of Aspira Pathlab&Diagn is ₹70 Crs. While the median market cap of its peers are ₹56 Crs.
Is Aspira Pathlab&Diagn financially stable compared to its competitors?
Aspira Pathlab&Diagn seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Aspira Pathlab&Diagn pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Aspira Pathlab&Diagn latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Aspira Pathlab&Diagn allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Aspira Pathlab&Diagn balance sheet?
Balance sheet of Aspira Pathlab&Diagn is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Aspira Pathlab&Diagn improving?
The profit is oscillating. The profit of Aspira Pathlab&Diagn is ₹0.84 Crs for TTM, -₹2.67 Crs for Mar 2024 and -₹0.09 Crs for Mar 2023.
Is the debt of Aspira Pathlab&Diagn increasing or decreasing?
Yes, The debt of Aspira Pathlab&Diagn is increasing. Latest debt of Aspira Pathlab&Diagn is -₹1.27 Crs as of Sep-24. This is greater than Mar-24 when it was -₹1.66 Crs.
Is Aspira Pathlab&Diagn stock expensive?
Yes, Aspira Pathlab&Diagn is expensive. Latest PE of Aspira Pathlab&Diagn is 82.83, while 3 year average PE is 13.67. Also latest EV/EBITDA of Aspira Pathlab&Diagn is 29.2 while 3yr average is 22.61.
Has the share price of Aspira Pathlab&Diagn grown faster than its competition?
Aspira Pathlab&Diagn has given better returns compared to its competitors. Aspira Pathlab&Diagn has grown at ~126.06% over the last 1yrs while peers have grown at a median rate of 26.26%
Is the promoter bullish about Aspira Pathlab&Diagn?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Aspira Pathlab&Diagn is 18.39% and last quarter promoter holding is 18.55%
Are mutual funds buying/selling Aspira Pathlab&Diagn?
There is Insufficient data to gauge this.